794 related articles for article (PubMed ID: 26463870)
1. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR; Scott BL; Boyd T; Garcia-Manero G
Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
[TBL] [Abstract][Full Text] [Related]
2. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2012 May; 72(8):1111-36. PubMed ID: 22571445
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
5. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2009; 69(17):2501-18. PubMed ID: 19911860
[TBL] [Abstract][Full Text] [Related]
8. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Laille E; Shi T; Garcia-Manero G; Cogle CR; Gore SD; Hetzer J; Kumar K; Skikne B; MacBeth KJ
PLoS One; 2015; 10(8):e0135520. PubMed ID: 26296092
[TBL] [Abstract][Full Text] [Related]
10. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
de Lima M; Oran B; Champlin RE; Papadopoulos EB; Giralt SA; Scott BL; William BM; Hetzer J; Laille E; Hubbell B; Skikne BS; Craddock C
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2017-2024. PubMed ID: 29933073
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
12. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Cluzeau T; Furstoss N; Savy C; El Manaa W; Zerhouni M; Blot L; Calleja A; Dufies M; Dubois A; Ginet C; Mounier N; Garnier G; Raynaud S; Rohrlich PS; Peterlin P; Stamatoullas A; Chermat F; Fenaux P; Jacquel A; Robert G; Auberger P
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881723
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
Font P
Adv Ther; 2011 Mar; 28 Suppl 3():1-9. PubMed ID: 21431628
[TBL] [Abstract][Full Text] [Related]
14. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
15. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Feld J; Tremblay D; Navada SC; Silverman LR
Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
[TBL] [Abstract][Full Text] [Related]
16. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
17. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Roboz GJ; Montesinos P; Selleslag D; Wei A; Jang JH; Falantes J; Voso MT; Sayar H; Porkka K; Marlton P; Almeida A; Mohan S; Ravandi F; Garcia-Manero G; Skikne B; Kantarjian H
Future Oncol; 2016 Feb; 12(3):293-302. PubMed ID: 26785287
[TBL] [Abstract][Full Text] [Related]
18. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
19. A pilot pharmacokinetic study of oral azacitidine.
Garcia-Manero G; Stoltz ML; Ward MR; Kantarjian H; Sharma S
Leukemia; 2008 Sep; 22(9):1680-4. PubMed ID: 18548103
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
Mozessohn L; Cheung MC; Fallahpour S; Gill T; Maloul A; Zhang L; Lau O; Buckstein R
Br J Haematol; 2018 Jun; 181(6):803-815. PubMed ID: 29767427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]